The Foundation for Financial Journalism (https://ffj-online.org/tag/valeant-pharmaceuticals/)
With Valeant Pharmaceuticals’ evolution from battleground stock to full-bore Wall Street circus, it is easy to forget that underneath the competing valuation narratives and regulatory drama is a real operating company.
Shortly before 11 p.m. on Feb. 4, Valeant Pharmaceuticals CEO Howard Schiller took off from Dulles International Airport for home. It had been a long, tiring day of preparation, congressional testimony with plenty of blunt questioning and afterward came the inevitable debriefing with his legal and public relations advisory team.
Valeant Pharmaceuticals is the type of company that tends to make even the simplest things complex.
Poland seems a most unlikely place for the next chapter of Valeant Pharmaceuticals’ saga to play out. Weighing in at about 3 percent of sales, the Polish operations are seemingly a modest contributor to Valeant’s fast growing bottom line.
On Valeant Pharmaceuticals’ conference call on Nov. 10, embattled chief executive J. Michael Pearson offered several defenses of his company’s internal controls and procedures.
The Southern Investigative Reporting Foundation’s story looking at Valeant Pharmaceuticals’ well-concealed relationship with Philidor Rx Services, struck a nerve.